Dr. Reddy’s is the First Participant in United States Pharmacopoeia’s
New Pharmaceutical Ingredient Verification Programme

Hyderabad, India, April 17, 2007: Dr. Reddy’s Laboratories Ltd. today announced that it has signed on as the first participant in United States Pharmacopoeia’s (USP) Pharmaceutical Ingredient Verification Programme.

“Participating in this programme shows that Dr. Reddy’s Laboratories shares USP’s commitment to good pharmaceutical care throughout the world,” said Dr. Roger Williams, Chief Executive Officer and Executive Vice-President of USP.

“We look forward to participating in this programme so that we can show manufacturers, regulatory authorities and consumers our dedication to producing pharmaceutical ingredients that are of consistently high quality,” said Satish Reddy, Chief Operating Officer and Managing Director of Dr. Reddy’s Laboratories Ltd.

USP created the Pharmaceutical Ingredient Verification Programme in response to increasing concerns throughout the pharmaceutical industry about the quality and consistency of pharmaceutical ingredients. The programme enables manufacturers to show the quality and integrity of their ingredients with a recognizable ‘USP Verified’ mark.

As a participant in the Pharmaceutical Ingredient Verification Programme, Dr. Reddy’s will submit ingredients to USP’s verification process, which includes:

• Evaluation of an ingredient manufacturer’s quality systems through an audit for compliance with Good Manufacturing Practices (GMPs)
• Review of manufacturing and quality control documents for the ingredients
• Laboratory testing of ingredient samples from USP-selected lots for compliance with USP’s FDA-enforceable standards for purity, potency and quality
• Post-verification surveillance testing of ingredients bearing the USP Verified mark.

Once each ingredient passes the verification process, Dr. Reddy’s will receive a Certificate of Standards Compliance. They will be permitted to post the ‘USP Verified’ mark on the shipping container, and certificate of analysis demonstrating that it meets USP’s world-class quality standards.

For more information on USP, please contact mediarelations@usp.org

About Dr. Reddy's:
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.

Disclaimer:
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

Contact Information:

Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-66511532

Media:
M Mythili at mythilim@drreddys.com or on +91-40-66511620.